Docetaxel: An update of its use in advanced breast cancer

Drugs

Volumn 59, Issue 3, 2000, Pages 621-651

  Figgitt, David P ^a   Wiseman, Lynda R ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EDATREXATE; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NAVELBINE; PACLITAXEL; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TOPOTECAN; TRASTUZUMAB; VINBLASTINE; VINCRISTINE;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CLINICAL TRIAL; COST UTILITY ANALYSIS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; FLUID RETENTION; HUMAN; MICROTUBULE ASSEMBLY; MONOTHERAPY; NEUTROPENIA; NONHUMAN; QUALITY OF LIFE; REVIEW;

EID: 0034008341     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059030-00015     Document Type: Review

References (191)

1. 1. Facts about breast cancer [online]. Available from URL: http://www.breastcancerinfo.com/bhealth/html/breastcancerf/acts.asp 1999 Oct 27; [2 pages]
2. 2. UK breast cancer awareness campaign [online]. Available from URL: http://www.easynet.co.uk/aware/ 1999 Oct 15; [1 page]
3. 3. Docetaxel launched and OCs nearer approval in Japan. Inpharma 1997 Jul 5; 1094: 21
4. 4. Breast cancer [online]. American Cancer Society - Cancer Facts and Figures 1998: Selected Cancers. [2 pages]. Available from URL: http://www.cancer.org/statistics/cff98/selectedcancers.html
5. 5. Perez EA. Current management of metastatic breast cancer. Semin Oncol 1999; 26 Suppl. 12: 1-10
6. 6. Fornier M, Munster P, Seidman AD. Update on the management of advanced breast cancer. Oncology 1999; 13: 647-58
7. 7. Aapro MS. Combining new agents with anthracyclines in metastatic breast cancer: an overview of recent findings. Semin Oncol 1999 Feb; 26 Suppl. 3: 17-21
8. 8. Eisenhauer EA, Vermorken JB. The taxoids: comparative clinical pharmacology and therapeutic potential. Drugs 1998 Jan; 55: 5-30
9. 9. Docetaxel (Taxotere): a new option for the treatment of homone-refractory prostate cancer. Proceedings of a symposium [Guest editor: Vogelzang, N]. Semin Oncol 1999; 26 (5) Suppl. 17: 1-68
10. 10. Fulton B, Spencer CM. Docetaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs 1996 Jun; 51: 1075-92
11. 11. Wiseman LR, Spencer CM. Paclitaxel: an update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancer. Drugs Aging 1998 Apr; 12: 305-34
12. 12. Hortobagyi GN. Recent progress in the clinical development of docetaxel (Taxotere). Semin Oncol 1999; 26 Suppl. 9: 32-6
13. 13. Mason K, Kishi K, Hunter N, et al. In vivo chemoradiotherapy with docetaxel and fractionated radiation [abstract no. 1705]. Proc Am Soc Clin Oncol 1999; 18: 442
14. 14. Milas L, Milas MM, Mason KA. Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol 1999; 9 (2) Suppl. 1: 12-26
15. 15. Banerjee S, Brown DL, Fallis AG, et al. Effects of taxotere on two human cancer cell lines [abstract no. 1541]. 88th Annu Meet Am Assoc Cancer Res 1997 Apr 12: 229
16. 16. Schimming R, Mason KA, Hunter N, et al. Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel. Cancer Chemother Pharmacol 1999 Feb; 43: 165-72
17. 17. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997; 57: 229-33
18. 18. Berchem GJ, Bosseler M, Mine N, et al. Nanomolar range docetaxel treatment sensitizes MCF-7 cells to chemotherapy induced apoptosis, induces G2M arrest and phosphorylates bcl-2. Anticancer Res 1999 Jan-Feb; 19: 535-40
19. 19. Kraus LA, Schmid SM, Coffield RT, et al. The mechanism of action of docetaxel and paclitaxel in xenograft models is not limited to Bcl-2 phosphorylation [abstract no. 3809]. Proceedings of the American Association Cancer Research 1999; 40: 578
20. 20. Barendsz-Janson AP, Toebes EAH, Hillen HFP, et al. Anti-angiogenic effect of tumor-drugs [abstract no. 298]. Ann Oncol 1998; 9 Suppl. 2: 78
21. 21. Plasencia C, Taron M, Abad A, et al. Cytotoxic effects of topotecan combined with various active G2/M phase anticancer drugs in panel of human tumor derived cell lines [abstract no. 647]. Ann Oncol 1998; 9 Suppl. 4: 135
22. 22. Ferlini C, Scambia G, Distefano M, et al. Synergistic anti-proliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis. Br J Cancer 1997; 75 (6): 884-91
23. 23. Chou TC, Otter GM, Sirotnak FM. Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro. Cancer Chemother Pharmacol 1996; 37: 222-8
24. 24. Hübner B, Eckert K, Maurer HR. Synergistic and antagonistic interactions between docetaxel and interferon-β on growth of human breast cancer cells in vitro. Int J Oncol 1996 Oct; 9: 625-8
25. 25. Hahm HA, Casero RA, Woster PM, et al. Combination therapy with polyamine analogs and chemotherapeutic agents in breast cancer cell lines, in vitro [abstract no. 3902]. Proceedings of the American Association Cancer Research 1999; 40: 592
26. 26. Konecny K, Pegram MD, Beryt M, et al. Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2/neu overexpression [abstract no. 467]. Breast Cancer Res Treat 1999; 57 (1): 114
27. 27. Zeng S, Fu T, Johnson KR, et al. In vitro evaluation of sequential-dependent combination of docetaxel and doxorubicin in human breast cancer cells [abstract no. 3884]. Proceedings of the American Association Cancer Research 1999 March; 40: 589
28. 28. Dykes DJ, Bissery MC, Harrison J SD, et al. Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere). Invest New Drugs 1995; 13: 1-11
29. 29. Bissery MC, Couteau C, Oulid-Aïssa D. Docetaxel in combination with irinotecan: prediction of clinical maximum tolerated dose [abstract]. 33rd Proc Am Soc Clin Oncol 1997 May 17; 16: 221
30. 30. Sawada N, Ishikawa T, Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 1998 Apr; 4: 1013-9
31. 31. Eckardt JR. Antitumor activity of docetaxel. Am J Health System Pharm 1997 Dec 15; 54 Suppl. 2: S2-6
32. 32. Mason KA, Hunter NR, Milas M, et al. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 1997 Dec; 3 (12 Pt 1): 2431-8
33. 33. Distelmans W, Storme G. The effect of pretreatment with docetaxel (taxotere; RP 56976) on irradiated subcutaneous MA 16/C murine tumors. J Exp Clin Cancer Res 1999; 18: 167-72
34. 34. Tampellini M, Filipski E, Liu XH, et al. Docetaxel chronopharmacology in mice. Cancer Res 1998 Sep 1; 58: 3896-904
35. 35. van Ark-Otte J, Samelis G, Rubio G, et al. Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phemitypes. Oncol Rep 1998 Jan-Feb; 5: 249-55
36. 36. Vanhoefer U, Cao S, Harstrick A, et al. Comparative antitumor efficacy of docelaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP). Ann Oncol 1997 Dec; 8: 1221-8
37. mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene 1998 Apr 23; 16: 2087-94
38. 38. Riou J-F, Naudin A, Lavelle F. Effects of taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 1992 Aug 31; 187: 164-70
39. 39. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999 Feb; 36: 99-114
40. 40. Bruno R, Sanderink GJ. Pharmacokinetics and metabolism of Taxotere™ (docetaxel). Cancer Surv 1993; 17: 305-13
41. 41. Aapro MS, Zulian G, Alberto P, et al. Phase I and pharmacokinetic study of RP 56976 in a new ethanol-free formulation of taxotere [abstract no. 208]. Ann Oncol 1992; 3 Suppl. 5: 53
42. 42. Burris H, Irvin R, Kuhn J, et al. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 1993 May; 11: 950-8
43. 43. Extra J-M, Rousseau F, Bruno R, et al. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993 Mar 1; 53: 1037-42
44. 44. Kearns CM. Pharmacokinetics of the taxanes. Pharmacotherapy 1997 Part 2, Sep-Oct 5; 17: 105S-9S
45. 45. Bruno R, Riva A, Hille D, et al. Pharmacokinetic and pharmacodynamic properties of docetaxel: results of phase I and phase II trials. Am J Health System Pharm 1997 Dec 15; 2 Suppl. 2: S16-19
46. 46. McLeod HL, Kearns CM, Kuhn JG, et al. Evaluation of the linearity of docetaxel pharmacokinetics. Cancer Chemother Pharmacol 1998 Jul; 42: 155-9
47. 1-acid glycoprotein. Invest New Drugs 1996; 14 (2): 147-51
48. 48. Veyrat-Follet C, Bruno R, Montay G, et al. Application of clinical trial simulation in exploring the safety profile of docetaxel (D) in cancer patients [abstract no. PIII-88]. Clin Pharmacol Ther 1999 Feb; 65: 198
49. 49. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998 Jan; 16: 187-96
50. 50. Bruno R, Vivier N, Montay G, et al. The cycle-to-cycle variability of docetaxel pharmacokinetics (PK) assessed by population PK analysis [abstract no. 751]. Eur J Cancer 1999; 35 Suppl. 4: S194
51. 51. Tanigawara Y, Sasaki Y, Otsu T, et al. Population pharmacokinetics of docetaxel in Japanese patients [abstract no. 1518]. Proc Am Soc Clin Oncol 1996 Mar; 15: 479
52. 52. Baker SD, Ravdin P, Aylesworth C, et al. A phase I and pharmacokinetic (PK) study of docetaxel in cancer patients with liver dysfunction due to malignancies [abstract no. 388]. Ann Oncol 1998; 9 Suppl. 2: 102
53. 53. de Valeriola D, Brassinne C, Kerger J, et al. Clinical and pharmacokinetic phase I study of docetaxel (TXT) combined to continuous infusion (CI) of 5-fluorouracil (FU) in advanced cancer patients [abstract no.774]. Proc Am Soc Clin Oncol 1997; 16: 221a
54. 54. Fumoleau P, Delecroix V, Perrocheau G, et al. Final results of a phase 1 dose finding and pharmacokinetic (P.K.) study of docetaxel in combination with vinorelbine in metastatic breast cancer [abstract no. 606P]. Ann Oncol 1996; 7 Suppl. 5: 126
55. 55. Schrijvers D, Pronk L, Highley M, et al. Sequence-dependent pharmacokinetics (PK) of ifosfamide (I) combined with docetaxel (D) [abstract no. OP 176]. Eur J Cancer A 1998 May; 34 Suppl. 2: S39
56. 56. Esposito M, Venturini M, Vannozzi MO, et al. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. J Clin Oncol 1999; 17 (4): 1132-40
57. 57. Cattel L, Airoldi M, Brusa P, et al. Pharmacokinetic (PK) interaction between epidoxorubicin (EPI) and docetaxel (TXT) in patients with metastatic breast cancer (MBC) [abstract no. 1318]. Eur J Cancer 1999; 35 Suppl. 4: S328
58. 58. Tranchand B, Peguy M, Guillot A, et al. A pharmacokinetic study of methotrexate and docetaxel given in association during a phase I trial [abstract no. 362]. Ann Oncol 1998; 9 Suppl. 2: 95
59. 59. Schüller J, Czejka M, Krexner E, et al. Pharmacokinetic (PK) interaction of the combination of doxorubicin (DOX) and Taxotere (TXT) [abstract no. 607O]. Ann Oncol 1998; 9 Suppl. 4: 126
60. 60. D'Incalci M, Schüller J, Colombo T, et al. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations. Semin Oncol 1998 Dec; 25 Suppl. 13: 16-20
61. 61. de Valeriola D, Awada A, Van Vreckem A, et al. Influence of amifostine (A) on the toxicity and pharmacokinetics (PK) of docetaxel (D) in breast cancer patients: an EORTIC-IDBBC study [abstract no. 76]. Eur J Cancer A 1998 Sep; 34 Suppl. 5: S19
62. 62. Schüller J, Czejka M, Krexner E, et al. Amifostine (AM) differently influences pharmacokinetics (PK) of selected cystostatic agents (CY) [abstract no. 1109]. Eur J Cancer A 1997 Sep; 33 Suppl. 8: S245
63. 63. Schellens JHM, Ma J, Bruno R, et al. Pharmacokinetics of cisplatin and Taxotere (docetaxel) and WBC DNA-adduct formation of cisplatin in the sequence Taxotere/cisplatin and cisplatin/Taxotere in a phase I/II study in solid tumor patients [abstract no. 323]. Proc Am Soc Clin Oncol 1994 Mar; 13: 132
64. 64. Bruno R, Vivier N, Houver C, et al. Lack of influence of dexamethasone premedication on docetaxel (Taxotere) pharmacokinetics [abstract no. 335]. Ann Oncol 1996; 7 Suppl. 1: 96
65. 65. Crown J. A review of the efficacy and safety of docetaxel as a monotherapy in metastatic breast cancer. Semin Oncol 1999 Feb; 26 Suppl. 3: 5-9
66. 66. Trudeau ME. Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer. Semin Oncol 1999; 26 Suppl. 8: 21-6
67. 67. Palacio I, Fra J, Lacave AJ, et al. The ideal dose of taxotere (T) in patients with metastatic breast cancer (MBC) previously treated with antracyclines (A): a dose finding study of the GON ("Grupo Oncologico del Norte") [abstract no. 14]. Eur J Cancer 1999 Apr; 35 Suppl. 2: S52
68. 2 is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy - a phase II single-center study. J Clin Oncol 1999 Apr; 17 (4): 1127-31
69. 69. Löffler TM, Dröge C, Hausamen TU. Update on dose-dense weekly Taxotere (R) in metastatic breast cancer [abstract no. O15]. Ninth International Congress on Anti-Cancer Treatment; 1999 Feb 2-5; Paris, France, 133
70. 70. Scholz U, Lück H-J, Rittershaus A, et al. Weekly docetaxel treatment in metastatic breast cancer: a phase I/II study [abstract no. 228]. Breast Cancer Res Treat 1998; 50 (3): 262
71. 71. Burstein HJ, Younger J, Bunnell CA, et al. Weekly docetaxel (Taxotere) for metastatic breast cancer: a phase II trial [abstract no. 484]. Proc Am Soc Clin Oncol 1999; 18: 127a
72. 72. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981 Jan; 47: 207-14
73. 73. Adachi I, Watanabe T, Takashima S, et al. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 1996 Jan; 73: 210-6
74. 74. Bonneterre J, Spielman M, Guastalla J-P, et al. Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience. Eur J Cancer 1999; 35 (10): 1431-9
75. 75. Alexopoulos CG, Rigatos G, Efremidou A, et al. Phase II study of taxotere monotherapy in previously treated patients (pts) with advanced breast cancer (ABC) [abstract no. 680]. Eur J Cancer A 1997 Sep; 33 Suppl. 8: S153
76. 76. Bonneterre J, Guastalla JP, Fumoleau P, et al. A phase II trial of docetaxel in patients (pts) with anthracycline resistant (AR) metasiatic breast cancer (MBC) [abstract no. 305]. Breast Cancer Res Treat 1996; 37 Suppl.: 89
77. 77. Coleman RE, Howell A, Eggleton SPH, et al. An open phase II study of taxotere in 42 patients with liver metastases from breast cancer [abstract no. 69P]. Ann Oncol 1998; 9 Suppl. 4: 15
78. 78. Constenla M, Carrete N, Lorenzo I, et al. Phase II trial of docetaxel and lenograstim in anthracycline-resistant metastatic breast cancer [abstract no. O20]. Ninth International Congress on Anti-Cancer Treatment; 1999 Feb 2-5; Paris, France, 134
79. 2 as 2nd line chemotherapy (CT) in patients (pts) with metastatic breast cancer (MBC) with stratification according to prognosis factors [abstract no. 78P]. Ann Oncol 1998; 9 Suppl. 4: 17
80. 80. Ferraresi V, Vaccaro A, Milella M, et al. Docetaxel (DT) in anthracycline-pretreated advanced breast cancer (ABC): toxicity and activity [abstract no. 88P]. Ann Oncol 1998; 9 Suppl. 4: 19
81. 81. Gorbounova V, Borisova T, Orel N. The increasing of effect after discontinuation of the treatment with Taxotere in patients with breast cancer [abstract no. 84]. Eur J Cancer A 1998 Sep; 34 Suppl. 5: S21
82. 82. Kusenda Z, Geurs F, Kerger J, et al. Docetaxel (D) activity in a compassionate-use program for "poor-risk" metastatic breast cancer (MBC): a single center experience [abstract no. 102P]. Ann Oncol 1996; 7 Suppl. 5: 24
83. 83. Litvachky A, Pescia A, Gramuglia V, et al. Phase IV, non-randomised, open trial of Taxotere (TXT) - single agent in anthracycline (A) relapsed metasiatic breast cancer (MBC) [abstract no. P39]. Ninth International Congress on Anti-Cancer Treatment; 1999 Feb 2-5; Paris, France, 193
84. 84. O'Brien MER, Leonard RC, Barrett-Lee PJ, et al. Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. Ann Oncol 1999 Feb; 10: 205-10
85. 85. Ravdin PM, Burris III HA, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995 Dec; 13: 2879-85
86. 86. Taguchi T, Mori S, Abe R, et al. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer [in Japanese]. Gan to Kagaku Ryoho 1994 Nov; 21: 2625-32
87. 87. Taguchi T, Hirata K, Kunii Y, et al. An early phase II clinical study of RP56976 (docetaxel) in patients with breast cancer [in Japanese]. Gan to Kagaku Ryoho 1994 Oct; 21: 2453-60
88. 88. Valero V, Jones SE, Von Hoff DD, et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998 Oct; 16 (10): 3362-8
89. 89. Van Vaerenbergh W, Paridaens R, Thomas J, et al. Docetaxel is a potent cytotoxic drug in the treatment of advanced breast cancer. Acta Clin Belg 1998 Aug; 53 (4): 264-9
90. 90. Vorobiof DA, Chasen MR, Moeken R. Phase II trial of single agent docetaxel in previously treated patients (pts) with advanced breast cancer (ABC) [abstract no. 138]. Ann Oncol 1996; 7 Suppl. 5: 31
91. 2 in locally advanced (LA) or metastatic breast cancer (MBC) [abstract no. 1283]. Eur J Cancer 1999; 35 Suppl. 4: S320
92. 92. Nabholtz J-M, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999 May; 17: 1413-24
93. 93. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 2341-23540
94. 94. Bonneterre J, Roche H, Monnier A, et al. Docetaxel (D) versus 5 fluorouracil-vinorelbine (FUN) in patients (pts) with metastatic breast cancer (MBC) as second line chemotherapy: a phase III study [abstract no. 223]. Breast Cancer Res Treat 1998; 50 (3): 261
95. 95. Sjöström J, Blomqvist C, Mouridsen H, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999; 35: 1194-201
96. 96. Löffler TM. Is there a place for "dose-dense" weekly schedules of the taxoids? Semin Oncol 1998 Oct; 25 Suppl. 12: 32-4
97. 97. Fumoleau P, Chevallier B, Kerbrat P, et al. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol 1996 Feb; 7: 165-71
98. 98. Trudeau ME, Eisenhauer EA, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996 Feb; 14: 422-8
99. 99. Borisova TA, Orel NF, Pirogova NA, et al. Phase II study of Taxotere in advanced or/and metastatic breast cancer as a first or second line of treatment [abstract no. 132]. Ann Oncol 1998; 9 Suppl. 4: 28
100. 100. Hudis CA, Seidman AD, Crown JP, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996 Jan; 14: 58-65
101. 101. Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995 Feb; 13: 314-22
102. -2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. Br J Cancer 1996 Aug; 74: 650-6
103. 103. Salimi M, Mir MR. Dose-dense weekly docetaxel and CBDCA in adriamycin-resistant metastatic breast cancer (MBC) [abstract no. 178]. Eur J Cancer A 1998 Sep; 34 Suppl. 5: S44
104. 104. Bernard A, Antoine E-C, Gozy M, et al. Docetaxel (D) and cisplatin (P) combination in anthracycline-pretreated advanced breast cancer (ABC): preliminary results of a phase II study [abstract no. 229]. Breast Cancer Res Treat 1997 Oct; 46: 58
105. 105. Llombart-Cussac A, Spielmann M, Dohollou N, et al. Cis-platinum-Taxotere phase I/II trial in patients with anthracyclin-resistant advanced breast cancer (ABC) [abstract no. 629]. 33rd Proc Am Soc Clin Oncol 1997 May 17; 16: 180a
106. 106. Martin M, Antón A, Esteban C, et al. FLEXI-TAC chemotherapy tor locally advanced breast cancer [abstract no. 019]. Ninth International Congress on Anti-Cancer Treatment; 1999 Feb 2-5; Paris, France, 134
107. 107. Polyzos A, Tsavaris N, Goga E, et al. A phase II study of docetaxel and epirubicin in patients with advanced breast cancer [abstract no. 122]. Anticancer Res 1998 Sep-Oct; 18: 3872
108. 108. Dent J, Dodwell D, Bradley C, et al. Phase I/II study of taxotere (T) in combination with epirubicin (E) and protracted venous infusion (PVI) 5-fluorouracil (F) in patients with recurrent or metastatic breast cancer (BC). A Yorkshire Collaborative Breast Cancer Study [abstract no. P291]. Br J Cancer 1999; 80 Suppl. 2: 101
109. 109. Ando M, Watanabe T, Sasaki Y, et al. A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer. Br J Cancer 1998 Jun; 77: 1937-43
110. 110. Cottu PH, Cojean-Zelek I, Lerebours F, et al. Docetaxel associated with 5-fluorouracil for patients with breast cancer: a phase I-II pilot study [abstract no. 42P]. Ann Oncol 1998; 9 Suppl. 4: 9
111. 111. Lortholary A, Maillart P, Delva R, et al. Docetaxel (D) in combination with continuous infusion 5fluorouracil (CI 5FU) in metastatic breast cancer (MBC) patients (pts) after anthracycline (ANT) failure: phase I dose-escalation [abstract no. 413]. Breast Cancer Res Treat 1997 Oct; 46: 96
112. 112. Michelotti A, Tibaldi C, Repetto L, et al. Taxotere in metastatic breast cancer patients pretreated with anthracycline and taxol [abstract no. 239]. Breast Cancer Res Treat 1998; 50 (3): 265
113. 113. Fountzilas G, Bafaloukos D, Nikolaides C, et al. Docetaxel (D) and gemcitabine (G) in anthracycline-resistant advanced breast cancer (AR-ABC) [abstract no. 121]. Ann Oncol 1998; 9 Suppl. 4: 26
114. 114. Mavroudis D, Malamos N, Alexopoulos A, et al. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcilabine: a multicenter phase II trial. Ann Oncol 1999 Feb; 10: 211-5
115. 115. von Minckwitz G, Costa S-D, Blohmer J, et al. Preoperative chemotherapy of breast carcinoma [in German]. Zentralbl Chir 1998; 123 Suppl. 5: 138-41
116. 116. Bueso P, Mayordomo JI, Cajal R, et al. Final report of a phase II trial with docetaxel + vinorelbine for anthracyclin-refractory metastasic breast cancer [abstract no. 24]. Eur J Cancer 1999 Apr; 35 Suppl. 2: S53
117. 117. Galvez C. Doxetaxel (D) in combination with vinorelbine (VNB) with GM-CSF in Taxol refractory metastatic breast cancer (MBC). Preliminary results of phase II [abstract no. P119]. Eighth International Congress on Anti-Cancer Treatment; 1998 Feb 3-6; Paris, France, 165
118. 118. Oncopaz Cooperative Group Study. Docetaxel-vinorelbine in anthracycline resistant disseminated breast carcinoma. An Oncopaz Cooperative Group Study [abstract no. 10]. Eur J Cancer 1999 Apr; 35 Suppl. 2: S52
119. 119. Baltali E, Özisik Y, Firat D, et al. Combination of docetaxel (T) and doxorubicin (D) as first-line chemotherapy in metastatic breast cancer (MBC) [abstract no. P42]. Ninth International Congress on Anti-Cancer Treatment; 1999 Feb 2-5; Paris, France, 194
120. 120. Nabholtz JM, Falkson G, Campos D, et al. A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC [abstract no. 485]. Proc Am Soc Clin Oncol 1999; 18: 127a
121. 121. Misset JL, Dieras V, Gruia G, et al. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol 1999; 10: 553-60
122. 122. Nabholtz J-M, Mackey J, Smylie M, et al. Taxane-based three-drug combination in metastatic and adjuvant treatment of breast cancer. Semin Oncol 1998 Oct; 25 (5) Suppl. 12: 27-31
123. 123. Palmeri S, Leonardi V, Ferraù F, et al. Doxorubicin (DXR) + docetaxel (DOC) as first line therapy of advanced breast cancer (ABC) patients: preliminary results of a multicentric phase II study [abstract no. 204]. Tumori 1998 Sep-Oct; 84 Suppl. 1: 84
124. 124. Sparano JA, Hu P, Schaefer PL, et al. Phase II trial of doxorubicin and docetaxel (Taxotere) plus granulocyte-colony stimulating factor (G-CSF) in metastatic breast cancer (MBC): an Eastern Cooperative Oncology Group Study (E1196) [abstract no. 27]. Breast Cancer Res Treat 1998; 50 (3): 233
125. 125. Vallejos C, Nunez P, Orlandi L, et al. Taxotere (T) and doxorubicin (D) combination: a phase II South American study in first line treatment (tt) of metastatic breast cancer (MBC) [abstract no. 1324]. Eur J Cancer 1999; 35 Suppl. 4: S329
126. 126. Shogan J, Troetschel M, Ellis P, et al. Phase II trial evaluating Adriamycin and Taxotere (AT) with GM-CSF support as first-line therapy for women with metastatic breast cancer [abstract no. 439]. Proc Am Soc Clin Oncol 1999; 18: 116
127. 127. Crown J, Fumoleau P, Kerhrat P, et al. Phase I trial of docetaxel (D) with cisplatin (P) as first-line chemotherapy of metastatic breast cancer (MBC) [abstract no. 821]. 33rd Proc Am Soc Clin Oncol 1997 May 17; 16: 233a
128. 128. Twelves C, Roche H, Vasey PA, et al. A phase I-II study of docetaxel (D) plus cyclophosphamide (C) as first line chemotherapy (CT) in metastatic breast cancer (MBC) [abstract no. 239]. Breast Cancer Res Treat 1997 Oct; 46 (1): 60
129. 129. Valero V. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors. Oncology Huntingt 1997 Aug; 11 (8) Suppl. 8: 34-6
130. 130. Fabi A, Venturini M, Michelotti A, et al. Combination of epirubicin (EPI) and Taxotere (TXT) with and without G-CSF in locally advanced (LABC) and metastatic breast cancer (MBC): a phase I-II study [abstract no. P72]. Ninth International Congress on Anti-Cancer Treatment; 1999 Feb 2-5; Paris, France, 201
131. 131. Kouroussis C, Xydakis E, Potamianou A, et al. Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. Ann Oncol 1999; 10: 547-52
132. 132. Pagani O, Sessa C, Martinelli G, et al. Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Ann Oncol 1999; 10: 539-45
133. 133. Kerbrat P, Viens P, Roché H, et al. Docetaxel (D) in combination with epirubicin (E) as 1st line chemotherapy (CT) of metastatic breast cancer (MBC): Final results [abstract no. 579]. Proc Am Soc Clin Oncol 1998; 17: 151a
134. 134. Kouroussis C, Androulakis N, Kakolyris S, et al. Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer. J Clin Oncol 1999 Mar; 17: 862-9
135. 135. Fumoleau P, Delecroix V, Perrocheau G, et al. Docetaxel (D) in combination with vinorelbine (V) as 1st line CT in pts with metastatic breast cancer (MBC): final results [abstract no. 232]. Proc Am Soc Clin Oncol 1996 Mar; 15: 142
136. 136. Sparano JA, Malik UR, Einzig A, et al. Phase I trial of liposomal doxorubicin (Doxil) and docetaxel (Taxotere) in patients (pts) with advanced breast cancer (ABC) [abstract no. 235]. Breast Cancer Res Treat 1998; 50 (3): 264
137. 137. Ravdin PM. Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer. Semin Oncol 1999; 26 Suppl. 9: 20-3
138. 138. Costa SD, von Minckwitz G, Raab G, et al. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer. Semin Oncol 1999; 26 Suppl. 9: 24-31
139. 139. Gademann G, von Minckwitz G, Costa S, et al. GEPARDO - a German trial of preop. chemotherapy with ADoc in breast cancer: first promising results [abstract no. 798]. Eur J Cancer 1999; 35 Suppl. 4: S205
140. 140. Gradishar WJ, Loh K, Erban J, et al. Preliminary results from a phase II study of (Taxotere) docetaxel as primary chemotherapy followed by doxorubicin and cyclophosphamide in stage III breast cancer [abstract]. Proc Am Soc Clin Oncol 1997 May 17; 16: 171
141. 141. Laurence V, Girre V, Extra JM, et al. Phase II study of sequential docetaxel (Taxotere, TXT) and doxorubicin (DOX) as primary chemotherapy (CT) for large operable breast cancer (BC) [abstract no. 791]. Eur J Cancer 1999; 35 Suppl. 4: S203
142. 142. Miller KD, McCaskill-Stevens W, Sisk J, et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 1999; 17: 3033-7
143. 143. Salimi M, Davaec M. Docetaxel and doxorubicin as neoadjuvant chemotherapy in locally - advanced breast cancer [abstract no. P10]. Ninth International Congress on Anti-Cancer Treatment; 1999 Feb 2-5; Paris, France, 186
144. 144. Smith IC, Hutcheon AW, Walker LG, et al. Primary chemotherapy in breast cancer: significantly enhanced clinical and pathological response with docetaxel [abstract no. 901]. Eur J Cancer 1999; 35 Suppl. 4: S230
145. 145. von Minckwitz G, Dan Costa S, Eiermann W, et al. Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 1999; 17: 1999-2005
146. 146. Wynendaele W, Paridaens R, Wildiers J, et al. Locally advanced breast cancer (LABC): neoadjuvant chemotherapy with sequential doxorubicin (DOX) and docetaxel (DOC) [abstract no. 813]. Eur J Cancer 1999; 35 Suppl. 4: S208
147. 147. Antoine EC, Chollet P, Monfardini S, et al. Sequential administration of docetaxel (D) (Taxotere) followed by AC in first line metastatic breast cancer (MBC) patients (pts): final results [abstract no. 91P]. Ann Oncol 1998; 9 Suppl. 4: 19-20
148. 148. Tubiana-Hulin M, Namer M, Tubiana-Mathieu M, et al. Alternating and sequential schedules of Taxotere/FEC 75 in the first line treatment of metastatic breast cancer [abstract no. 57O]. Ann Oncol 1998; 9 Suppl. 4: 12
149. 149. Valencak J, Kornek GV, Haider K, et al. Treatment of advanced refractory breast cancer with docetaxel alternating with epirubicin and cyclophosphamide (EC) + G-CSF [abstract no. 689]. Ann Oncol 1998; 9 Suppl. 2: 180
150. 150. Mendez M, Quiben R, López P. Sequential therapy of taxol followed by vinorelbine and cisplatin as second line in advanced breast cancer [abstract no. 1309]. Eur J Cancer 1999; 35 Suppl. 4: S326
151. 151. Paridaens R, Van Aelst F, Georgoulias G, et al. A phase II randomized study of doxorubicin (A) alternated to docetaxel (T) (ALT) vs sequential administration of 4 cy of t followed by 4 cy of a (seq) as 1st line et in mbc pts [abstract no. 1259]. Eur J Cancer 1999; 35 Suppl. 4: S314
152. 152. Koroleva I, Wojtukiewicz M, Zaluski J, et al. Preliminary data of a phase II randomized trial of taxotere (TXT) and doxorubicin (DOX) given simultaneously or sequentially as 1st line chemotherapy (CT) for metastatic breast cancer (MBC) [abstract no. 1272]. Eur J Cancer 1999; 35 Suppl. 4: S317
153. 153. Lamb HM, Wiseman LR. Docetaxel: a pharmacoeconomic review of its use in the treatment of metastatic breast cancer. Pharmacoeconomics 1998 Oct; 14: 447-59
154. 154. Peters BG, Dunphy IF, Hill JJ. Docetaxel and paclitaxel for the treatment of anthracycline-resistant metastatic breast cancer: a pharmacoeconomic model. P&T 1997 Nov; 22: 543-52
155. 155. Launois R, Reboul-Marty J, Henry B, et al. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer: docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics 1996 Nov: 10: 504-21
156. 156. Brown RE, Hutton J. Cost utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anticancer Drugs 1998 Nov; 9: 899-907
157. 157. Hutton J, Brown R, Borowitz M, et al. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics 1996; 9 Suppl. 2: 8-22
158. 158. Leung PP, Tannock IF, Oza AM, et al. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracyctine-resistant breast cancer. J Clin Oncol 1999; 17 (10): 3082-90
159. 159. Ajani JA, Welch SR, Raber MN, et al. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990; 8: 147-59
160. 160. World Health Organization. Handbook for reporting results of cancer treatment. WHO publication no. 48 ed. Geneva, Switzerland: World Health Organization, 1979
161. 161. Furue H, Hara Y, Imai Y, et al. Criteria for the evaluation of effect reinforcement of solid cancer chemotherapy [in Japanese]. Nippon Gan Chiryo Gakkai Shi 1986; 21: 943-53
162. 162. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995 Oct; 13: 2643-55
163. 163. Balmaceda C, Forsyth P, Seidman AD, et al. Peripheral neuropathy in patients receiving taxotere chemotherapy [abstract]. Ann Neurol 1993 Aug; 34: 313
164. 164. van den Bent MJ, Hilkens PHE, Verwey J, et al. Docetaxel induces a mild dose-dependent sensory neuropathy [abstract no. 574P]. Neurology 1995 Apr; 45 Suppl. 4: A322
165. 165. Pronk LC, Hilkens PHE, van den Bent MJ, et al. Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel. Anticancer Drugs 1998 Oct; 9: 759-64
166. 166. Pronk LC, van Putten WLJ, van Beurden V, et al. The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: results of a comparative study. Cancer Chemother Pharmacol 1999; 43: 173-7
167. 167. Behar A, Pujade-Lauraine E, Maurel A, et al. The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. Br J Clin Pharmacol 1997 Jun; 43: 653-8
168. 168. Oulid-Aïssa D, Béhar A, Spielmann M, et al. Management of fluid retention syndrome in patients treated with Taxotere (docetaxel): effect of premedication [abstract no. 1614]. Proc Am Soc Clin Oncol 1994 Mar; 13: 465
169. 169. Semb KA, Aamdal S, Øian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 1998 Oct; 16: 3426-32
170. 170. Webster LK, Linsenmeyer ME, Rischin D, et al. Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide. Cancer Chemother Pharmacol 1997 Apr; 39: 557-60
171. 171. Chan S, Winterbottom L, Gardner S. Response to dexamethasone in patients with fluid retention after docetaxel [letter]. Lancet 1996 May 25; 347: 1486-7
172. 172. Riva A, Fumoleau P, Roché H, et al. Efficacy and safety of different corticosteroid (C) premedications (P) in breast cancer (BC) patients (pts) treated with Taxotere (T) [abstract no. 660]. 33rd Proc Am Soc Clin Oncol 1997 May 17; 16: 188a
173. 173. Piccart MJ, Klijn J, Paridaens R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997 Sep; 15: 3149-55
174. 174. Aventis Pharma. Taxotere (docetaxel) US prescribing information. Collegeville, PA., USA, 1999
175. 175. Aventis. Taxotere (docetaxel) European summary of product characteristics. Antony Cedex, France, Jan 2000
176. 176. Wanders J, Schrijvers D, Bruntsch U, et al. The EORTC-ECTG experience with acute hypersensitivity reactions (HSR) in Taxotere studies [abstract no. 94]. Proc Am Soc Clin Oncol 1993 Mar; 12: 73
177. 177. Nabholtz J-M, Mackey JR, Smylie M, et al. Final results of a phase II study of taxotere (docetaxel, D), doxorubicin and cyclophosphamide in the treatment of metastatic breast cancer [abstract]. Eur J Cancer A 1998 Sep; 34 Suppl. 5: 43
178. 178. Llombart-Cussac A, Pivot X, Spielmann M. Docetaxel chemotherapy induces transverse superficial loss of the nail plate [letter]. Arch Dermatol 1997 Nov; 133: 1466-7
179. 179. Auvinet M, Dahan S, Dingremont C, et al. Yellow nails [in French]. Rev Med Interne 1998 May; 19: 353-4
180. 180. Vanhooteghem O, André J, Vindevoghel A, et al. Docetaxel-induced subungual hemorrhage. Dermatology 1997; 194: 419-20
181. 181. Nabholtz J-M. Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer. Semin Oncol 1999 June; 26 (3) Suppl. 9: 7-13
182. 182. Di Leo A, Crown J, Nogaret LM, et al. Doxorubicin (A) followed by docetaxel (T) versus doxorubicin + docetaxel in the adjuvant treatment of breast cancer (BC) [abstract no. 166]. Eur J Cancer 1998; 34 Suppl. 5: S41
183. 183. Sparano JA. Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics. Semin Oncol 1999; 26 Suppl. 9: 14-9
184. 184. Consensus summary on breast cancer. Semin Oncol 1999 Feb; 26 Suppl. 2: 27
185. 185. Luoma L, Hakamies-Blomqvist M-L, Sjöström J, et al. Preliminary results from quality of life (QOL) study in metastatic breast cancer: a randomised study comparing Taxotere (T) to sequential methotrexate-fluorouracil (MF) in advanced anthracycline resistant breast cancer, a phase III study [abstract no. 245]. 34th Proc Am Soc Clin Oncol 1998 May 16-19; 17: 63
186. 186. Mouridsen HT. Systemic therapy of advanced breast cancer. Drugs 1992; 44 Suppl 4: 17-28
187. 187. Rubens RD. Key issues in the treatment of advanced breast cancer: expectations and outcomes. Pharmacoeconomics 1996; 9 Suppl. 2: 1-7
188. 188. de Valeriola D, Awada A, Roy J-A, et al. Breast cancer therapies in development. A review of their pharmacology and clinical potential. Drugs 1997 Sep; 54 (3): 385-413
189. 189. Brown RE, Burrell A. The economic advantages of response in the treatment of advanced breast cancer. J Drug Assess 1999; 2 (2): 181-7
190. 190. Perry CM, Wiseman LR. Trastuzumab. Biodrugs 1999; 12 (2): 129-35
191. 191. Burris HA, Raefsky E, Albain K, et al. Docetaxel and Herceptin as first-or second-line therapy for women with HER-2 over-expressing metastatic breast cancer [abstract no. 518]. Breast Cancer Res Treat 1999; 57 (1): 123